Solvent/Detergent Plasma

Production of Plasma Proteins for Therapeutic Use

Volumn , Issue , 2012, Pages 345-357

  Svae, Tor Einar ^a   Heger, Andrea ^b   Biesert, Lothar ^c   Neisser Svae, Andrea ^a   Frenzel, Wolfgang ^a  

^a Octapharma AG   (Switzerland)

^b Octapharma Pharmazeutika Produktions GmbH   (Austria)

^c Octapharma Pharmazeutika Produktions GmbH   (Germany)

Author keywords

Clinical safety and tolerability; Pathogen safety; S D plasma from Octapharma; S D treated plasma; Virus inactivation kinetics

Indexed keywords

EID: 84886202448     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118356807.ch25     Document Type: Chapter

References (87)

1. Horowitz B. (2010). United States: solvent/detergent plasma. In: Pathogen inactivation: the penultimate paradigm shift, (AuBuchon JP, Prowse CV, eds.). AABB Press, Bethesda, MD, pp. 217-228.
2. Kerner B. (1995) Good manufacturing practice and viral safety. Blood Coagul Fibrinolysis, 6, 15-19.
3. Heiden M, Seitz R. (2002) Quality of therapeutic plasma-requirements for marketing authorisation. Thromb Res, 107, S47-S51.
4. Solheim BG, Hellstern P. (2003) Composition, efficacy, and safety of S/D-treated plasma. Transfusion, 43, 1176-1178.
5. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M. (2006) Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med, 16, 266-275.
6. Tølløfsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG. (2003) Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med, 29, 1736-1743.
7. Solheim BG, Granov DA, Juravlev VA, Krawczyk M, Kubishkin VA, Patutko UI, Raab R. (2005) Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang, 89, 19-26.
8. Chekrizova V, Murphy WG. (2006) Solvent/detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med, 16, 85-91.
9. Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. (1993) Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis, 4, 599-604.
10. Hellstern P, Larbig E, Walz GA, Thürigen W, Oberfrank K. (1993) Prospective study on efficacy and tolerability of solvent/detergent plasma in intensive care unit patients. Infusionsther Transfusionmed, 20, 16-18.
11. Solheim BG, Svennevig JL, Mohr B, Dragsund M, Noddeland H, Töllefsrud S, Brosstad F, Rollag H, Mollnes TE. (1993) The use of Octaplas in patients undergoing open heart surgery. In: DIC: pathogenesis, diagnosis and therapy of disseminated intravascular fibrin formation, (Müller-Berghaus G, eds.). Elsevier Science Publishers B.V., pp. 253-262.
12. Hellstern P, Sachse H, Schwinn H, Oberfrank K. (1992) Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang, 63, 178-185.
13. Heger A, Svae T-E, Neisser-Svae A, Jordan S, Behizad M, Römisch J. (2009) Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang, 97, 219-225.
14. Heger A, Römisch J, Svae T-E. (2005) Stability of solvent/ detergent-treated plasma and single-donor fresh-frozen plasma during 48h after thawing. Tranfus Apher Sci, 33, 257-267.
15. Buchta C, Felfernig M, Höcker P, Macher M, Körmöczi GF, Quehenberger P, Heinzl H, Knöbl P. (2004) Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4°C for 6 days. Vox Sang, 87, 182-186.
16. Brown P. (2007) Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia, 13 (Suppl. 5), 33-40.
17. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. (1998) Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang, 74 (Suppl. 1), 203-206.
18. Morfeld F, Schütz R, Josic D, Schwinn H. (1996) Manufacturing and down scaling process for a virus-inactivated pooled human plasma. Pharm Ind, 58, 433-435.
19. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. (1992) Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood, 79, 826-831.
20. Josic D, Schulz P, Biesert L, Hoffer L, Schwinn H, Kordis-Krapez M, Strancar A. (1997) Review: issues in the development of medicinal products based on human plasma. J Chromatogr B, 694, 253-269.
21. Biesert L, Suhartono H. (1998) Solvent/detergent treatment of human plasma-a very robust method for virus inactivation. Validated virus safety of Octaplas®. Vox Sang, 74 (Suppl. 1), 207-212.
22. Roberts P. (2000) Resistance of Vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals, 28, 29-32.
23. Offergeld R, Faensen D, Ritter S, Hamouda O. (2005) Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of full nucleic acid amplification testing. Euro Surveill, 10, 8-11.
24. Jutzi M, Levy G, Taleghani BM. (2008) Swiss haemovigilance data and implementation of measures for prevention of transfusion associated acute lung injury (TRALI). Transfus Med Hemother, 35, 98-101.
25. Kitchen AD, Barbara JAJ. (2008) Current information of the infectious risk of allogenic blood transfusion. Transfus Altern Transfus Med, 10, 102-111.
26. Dodd RY, Notari EPIV, Stramer SL. (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42, 975-979.
27. Tocci LJ, Napychank PA, Cable RG, Snyder EL. (1993) The effect of solvent/detergent-treated plasma on stored platelet concentrates. Transfusion, 33, 145-149.
28. Geiger TL, Pisciotto PT, Baril LL, Snyder EL. (1995) The effect of solvent/detergent-treated plasma on red cells stored in vitro. Transfusion, 35, 487-492.
29. Rollag H, Solheim BG, Svennevig J. (1998) Viral safety of blood derivatives by immune neutralisation. Vox Sang, 74 (Suppl. 1), 213-217.
30. Lim YA, Hyun BH, Kim DY. (2002) Effect of transfusion of fresh-frozen plasma on recipients' antibodies to hepatitis B surface antigen and hepatitis B surface antigen status in countries where hepatitis B virus is endemic. Vox Sang, 83, 209-213.
31. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. (2000) Viral safety of solvent/detergent-treated plasma. Transfusion, 40, 84-90.
32. Koenigbauer UF, Eastlund T, Day JW. (2000) Clinical illness due to parvovirus B19 infection after infusion of solvent/ detergent-treated pooled plasma. Transfusion, 40, 1203-1206.
33. Lee KK, Vargo LR, Lê CT, Fernando L. (1992) Transfusionacquired hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit. Ped Infect Dis J, 11, 122-123.
34. Jordan J, Tiangco B, Kiss J, KochW. (1998) Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinicaloutcomesoftransfusionrecipients. VoxSang, 75, 97-102.
35. Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, Lelie PN. (1993) Hepatitis A antibody titres after infection and immunization: implications for passive and active immunisation. J Med Virol, 40, 22-27.
36. Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, Aberham, Gessner M, Kreil TR. (2008) Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion, 48, 178-186.
37. Tabor E, Epstein JS. (2002) NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion, 42, 1230-1237.
38. Stramer SL. (2006) Impact of NAT on serological screening of transfusion-transmitted agents. ISBT Sci Ser, 1, 194-202.
39. Peden A, McCardle L, HeadMW, Love S,Ward HJT, Cousens SN, Keeling DM, Millard CM, Hill FGH, Ironside JW. (2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia, 16, 296-304.
40. Svae T-E, Neisser-Svae A, Bailey A, Reichl H, Biesert L, Schmidt T, Heger A, Römisch J. (2008) Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Tranfus Apher Sci, 39, 59-67.
41. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P. (2003) Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion, 43, 1687-1694.
42. Neisser-Svae A, Bailey A, Gregori L, Heger A, Jordan S, Behizad M, Reichl H, Römisch J, Svae T-E.(2009) Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG®. Vox Sang, 97, 226-233.
43. Borkent-Raven BA, Janssen P, van der Poel CL, Schaasberg WP, Bonsel GJ, van Hout BA. (2011) Survial after transfusion in the Netherlands. Vox Sang, 100, 196-203.
44. Beeck H, Hellstern P. (1998) In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang, 74 (Suppl. 1), 219-223.
45. Heger A, Römisch J, Svae T-E. (2006) A biochemical comparison of pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Tranfus Apher Sci, 35, 223-233.
46. Pock K, Heger A, Janisch S, Svae T-E, Römisch J. (2007) Thrombin generation capacity is impaired in methylene blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas®) and a development product (Uniplas1). Tranfus Apher Sci, 37, 223-231.
47. Heger A, Kannicht C, Römisch J, Svae T-E. (2007) Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas®) and in the universally applicable plasma (Uniplas) in development. Vox Sang, 92, 206-212.
48. Lawrie AS, Green L, Canciani MT, Mackie IJ, Peyvandi F, Scully MA, Machin SJ. (2010) The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang, 99, 232-238.
49. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol, 121, 778-785.
50. de Jonge J, Groenland THN Metselaar HJ, Ijzermans JNM, van Vliet HHDM, Visser L, Tilanus HW. (2002) Fibrinolysis during liver transplantation is enhanced by using solvent/ detergent virus-inactivated plasma (ESDEP®). Anesth Analg, 94, 1127-1131.
51. Tek I, Arslan Ö, Arat M, Özcan M, Akdag B, Ilhan O. (2003) Effects of replacement fluids on coagulation system used for therapeutic plasma exchange. Tranfus Apher Sci, 28, 3-7.
52. Flamholz R, Jeon H-R, Baron JM, Baron BW. (2000) Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thrombosis. J Clin Apheresis, 15, 169-172.
53. Coignard P, Colquhoun SD, Nguyen GT, Tokars JI, McMillian M, Mascola L, Shackleton CR, Jarvis WR. (2002) Intraoperative deaths in liver transplant recipients associated with the use of solvent/detergent plasma. Hepatology, 36, AASLD abstract 171, 209A.
54. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. (1999) Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood, 94, 3922-3927.
55. Hellstern P. (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol, 11, 346-350.
56. Sinnott P, Bodger S, Gupta A, Brophy M. (2004) Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas®). Eur J Immunogenet, 31, 271-274.
57. Sachs UJH, Kauschat D, Bein G. (2005) White blood cellreactive antibodies are undetectable in solvent/detergent plasma. Transfusion, 45, 1628-1631.
58. Arnold DM, Blajchman MA, DiTomasso J, Kulczycki M, Keith PK. (2007) Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med, 167, 853-854.
59. Domen RE, Hoeltge GA. (2003) Allergic transfusion reactions. An evaluation of 273 consecutive reactions. Arch Pathol Lab Med, 127, 316-320.
60. Lutze G, Hartung KJ. (1994) Gerinnungsfaktoren. Aktivitätsund Konzentrationsbestimmungen in konventionellen und virusinaktivierten gerinnerungsaktiven Plasmen. Krankenhauspharmazie, 9, 517-522.
61. Barz D. (1994) Detection of antigen structures in blood cells in differently prepared plasma preparations. Anaesthesiol Reanimate, 19, 155-158.
62. Win N, Massey E, Lucas G, Sage D, Brown C, Green A, Contreras M, Navarrete C. (2007) Ninety-six suspected transfusion-related acute lung injury cases: investigation findings and clinical outcome. Hematology, 12, 461-469.
63. Chapman CE, Stainsby D, Jones H, Love E, Massey E,Win N, Navarette C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM, on behalf of the Serious Hazards of Transfusion Steering Group. (2009). Ten years of haemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 49, 440-452.
64. Wiersum-Osselton JC, Middelburg RA, Beckers EA, van Tilborg AJW, Zijlker-Jansen PY, Brand A, van der Bom JG, Scipperus MR. (2011) Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-andafter comparative cohort study. Transfusion, 51, 1537-2995.
65. Eder AF, Herron RM, Jr., Strupp A, Dy B, White J, Notari EP, Dodd RY, Benjamin RJ. (2010) Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion, 50, 1732-1742.
66. Bux J, Sachs UJH. (2007) The pathogenesis of transfusionrelated acute lung injury (TRALI). Br J Haematol, 136, 788-799.
67. Connolly M, Erber WN, Grey DE. (2005) Case report: immune anti-D stimulated by transfusion of fresh frozen plasma. Immunohematology, 21, 149-151.
68. Gilstad CW. (2003) Anaphylactic transfusion reactions. Curr Opin Hematol, 10, 419-423.
69. Reutter JC, Sanders KF, BrecherME, Jones HG, Bandarenko N. (2001) Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apheresis, 16, 134-138.
70. Vaara I, Nilsson CD. (2010) SD-plasma säkrare än färskfrusen plasma. Läkartidningen, 107, 106-107.
71. Ring J, Laubenthal H, Meßmer K. (1982) Incidence and classification of adverse reactions to plasma substitutes. Klin Wochenschr, 60, 9971-1002.
72. Solheim BG, Hellstern P. (2010) Pathogen inactivation of plasma and cryoprecipitate. In: Pathogen inactivation: the penultimate paradigm shift, (AuBuchon JP, Prowse CV, eds.). AABB Press, Bethesda, MD, pp. 69-98.
73. Serious Hazards of Transfusion (SHOT). Annual Reports 2007, 2008, and 2009. www.shotuk.org/home. Accessed November 9, 2011.
74. Flesland O. (2007) A comparison of complication rates based on published haemovigilance data. Intensive Care Med, 33 (Suppl. 1), S17-S21.
75. Andreu G. (2010) France: solvent/detergent plasma. In: Pathogen inactivation: the penultimate paradigm shift, (AuBuchon JP, Prowse CV, eds.). AABB Press, Bethesda, MD, pp. 137-151.
76. Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, Clarke G, Ambruso DR. (2003) Transfusion-related acute lung injury: epidemiology and prospective analysis of etiologic factors. Blood, 101, 454-462.
77. Keller-Stanislawski B, Reil A, Günay S, Funk MB. (2010) Frequency and severity of transfusion-related acute lunginjury-German haemovigilance data (2006-2007). Vox Sang, 98, 70-77.
78. Wallis JP, Lubenko A, Wells AW, Chapman CE. (2003) Single hospital experience of TRALI. Transfusion, 43, 1053-1059.
79. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. (2007) Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion, 47, 599-607.
80. Gajic O, Rana R,Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB. (2007) Transfusionrelated acute lung injury in the critically ill. Prospective nested case-control study. Am J Respir Crit Care Med, 176, 886-891.
81. Wright SE, Snowden CP, Athey SC, Leaver AA, Clarkson J-M, Chapman CE, Roberts DRD, Wallis JP. (2008) Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med, 36, 1796-1802.
82. Krusius T, Auvinen M-K, Nikkinen L. (2009) Introduction of Octaplas® in clinical use decreased the rate of severe adverse reactions. Vox Sang, 96 (Suppl. 1), 33, abstract 3A-S13-03.
83. De Silvestro G, Bagatella P, Tison T, Quaino V, Carraro P, Tenderini ML, Lazzaro A, Marotti A. (2007) Virus-inactivated plasma-Plasmasafe: a one-year experience. Blood Transfus, 5, 134-142.
84. Demeyere R, Gilliardin S, Arnout J, Strengers PFW. (2010) Comparison of fresh-frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang, 99, 251-260.
85. Edel E, Al-Ali HK, Seeger S, Kauschat D, Matthes G. (2010) Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: a single-center experience. Transfus Med Hemother, 37, 13-19.
86. Riedler GF, Haycox AR, Duggan AK, Dakin HA. (2003) Costeffectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang, 85, 88-95.
87. van Eerd MC, Mario Ouwens JN, de Peuter MA. (2010) Costeffectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically ill patients in the UK. Tranfus Apher Sci, 43, 251-259.